Open–label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study
ID Number 17-0873Principal Investigator(s)
Department(s) or Division(s)
Pulmonary, Critical Care and Sleep Medicine
The purpose of this study is to evaluate the safety, tolerability, and secondarily the effectiveness of dupilumab, in the treatment of moderate to severe uncontrolled asthma, when administered by injection under the skin every 2 weeks for about 2 years.
Participants in this study will receive dupilumab, administered by subcutaneous injection (injection under the skin). If they are entering this study from the DRI12544 study, they will have an injection of 600 mg on study Day 1, and then 300 mg every 2 weeks (every other week) for up to 2 years. If they are entering the study from the PDY14192, EFC13579, or EFC13691 studies, they will not have a 600 mg injection on study Day 1, but will continue the 300 mg injections every 2 weeks, following the same schedule they used in the first study.
Recruiting Patients: No